GlassScriptPhysician profile
Cindy A Leissinger
NPI 1700839933
$134,904.64
in general payments reported to CMS, 2019-2025
32 companies · $683 in 2025
The $683 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43K · 2020: $37K · 2021: $25K · 2022: $14K · 2023: $10K · 2024: $5,335 · 2025: $683.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,030 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,018 · Travel and Lodging: $712 · Food and Beverage: $661.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,030.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,017.87 |
| Travel and Lodging | $712.21 |
| Food and Beverage | $661.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $27,559.42 | 2019-2025 | Hemgenix, Idelvion, Afstyla |
| Takeda Pharmaceuticals U.S.A., INC. | $26,868.52 | 2019-2025 | Vonvendi |
| Shire North American Group INC | $23,567.80 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $12,913.65 | 2019-2023 | |
| Global Blood Therapeutics, INC. | $10,414.17 | 2021 | |
| Pfizer INC. | $8,603.82 | 2022-2025 | |
| Dova Pharmaceuticals | $6,015.85 | 2020-2021 | |
| Genentech USA, INC. | $4,750.77 | 2019-2025 | Hemlibra |
| Bioverativ Therapeutics INC. | $3,842.00 | 2020 | |
| Biomarin Pharmaceutical INC. | $3,236.59 | 2022-2023 | |
| Kedrion Biopharma INC. | $2,600.00 | 2019 | |
| Chiesi USA, INC. | $2,100.00 | 2020 | |
| Genzyme Corporation | $1,856.46 | 2020-2021 | |
| Emd Serono, INC. | $111.15 | 2019 | |
| Novartis Pharmaceuticals Corporation | $83.70 | 2019-2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $73.61 | 2019-2024 | Keytruda |
| Novo Nordisk INC | $69.46 | 2019 | |
| Astellas Pharma US INC | $46.90 | 2023-2024 | Xtandi, Xospata |
| Hema Biologics, LLC | $29.86 | 2022 | |
| Daiichi Sankyo INC. | $27.86 | 2024 | Vanflyta |
| Abbvie INC. | $23.29 | 2025 | |
| Alexion Pharmaceuticals, INC. | $21.48 | 2019 | |
| Spark Therapeutics, INC. | $20.50 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $19.18 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $18.88 | 2019 | |
| Lilly USA, LLC | $15.28 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $14.44 | 2019 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cindy Leissinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.